Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Launches Exforge OD Tablets
June 22, 2015
- Daiichi Sankyo Initiates Multinational PIII Study of Edoxaban for Venous Thromboembolism in Cancer
June 22, 2015
- Japan to Participate in Asian PIII Trial of NC-6004 for Pancreatic Cancer: NanoCarrier
June 19, 2015
- 30 Companies Obtain Listing for Plavix Generics
June 19, 2015
- JCR, Sumitomo Dainippon Collaborate in Blood-Brain Barrier Penetration Technology for Drug Discovery
June 19, 2015
- Generic Market to Grow 9.4% in FY2015: Yano Research
June 18, 2015
- Japanese Generic Market to Reach 867.9 Billion Yen in FY2014: Survey
June 17, 2015
- Taiho Licenses Lonsurf to Servier of France for Europe
June 16, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Lenvima More Beneficial to Patients against Sorafenib: Dr Tahara of National Cancer Center
June 15, 2015
- Carna Biosciences Licenses Its Kinase Inhibitor to Janssen Biotech of US
June 15, 2015
- Toujeo Shows Similar Glycemic Control to Lantus in PIII Study in Japanese Patients: Sanofi
June 12, 2015
- PeptiDream to Receive Milestone Payments from BMS for Designating Clinical Candidate Compound
June 12, 2015
- FY2014 Earnings of 24 Major Japanese Drug Makers: Jiho Tally
June 12, 2015
- NanoCarrier to Initiate PI Study of NC-6004 for Head, Neck Cancer in Japan
June 11, 2015
- Novartis Has High Hopes for T-Cell Therapy CTL019
June 10, 2015
- Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
- No Difference from Clinical Trials in Incidence of Adverse Reactions to SGLT-2 Inhibitor: Prof. Kaku of Kawasaki Medical School
June 10, 2015
- R-Tech Ueno Partners with Autonomous University of Barcelona in Research for Development of VAP-1 Inhibitor
June 10, 2015
- Highlights of FY2014 Earnings - Part 5: Lackluster 1% Sales Growth Likely in FY2015
June 10, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…